Tsikitis Vassiliki L, Malireddy Kishore, Green Erin A, Christensen Brent, Whelan Richard, Hyder Jace, Marcello Peter, Larach Sergio, Lauter David, Sargent Daniel J, Nelson Heidi
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN 55905, USA.
J Clin Oncol. 2009 Aug 1;27(22):3671-6. doi: 10.1200/JCO.2008.20.7050. Epub 2009 Jun 29.
Intensive postoperative surveillance is associated with improved survival and recommended for patients with late stage (stage IIB and III) colon cancer. We hypothesized that stage I and IIA colon cancer patients would experience similar benefits.
Secondary analysis of data from the Clinical Outcomes of Surgical Therapy trial was performed by analyzing results according to TNM stage; early (stage I and IIA, 537 patients) and late (stage IIB and III, 254 patients) stage disease. Five-year recurrence rates were higher in patients with late (35.7%) versus early stage disease (9.5%). Early and late stage salvage rates, recurrence patterns and methods of first detection were compared by chi(2) test.
Salvage rates for early- and late-stage disease patients with recurrence were the same (35.9% v 37%; P = .9, respectively). Median survival after second surgery after recurrence was 51.2 and 35.8 months for early- and late-stage patients, respectively. Single sites of first recurrence did not significantly differ between early and late stage, but multiple sites of recurrence occurred less often in early-stage patients (3.6% v 28.6%, for early v late, respectively; P < .001). METHODS of first detection of recurrence were not significantly different: carcinoembryonic antigen (29.1% v 37.4%), computed tomography scan (23.6% v 26.4%), chest x-ray (7.3% v 12.1%), and colonoscopy (12.7% v 8.8%), for early versus late stage disease, respectively.
Patients with early-stage colon cancer have similar sites of recurrence, and receive similar benefit from postrecurrence therapy as late-stage patients; implementation of surveillance guidelines for early-stage patients is appropriate.
强化术后监测与生存率提高相关,推荐用于晚期(IIB期和III期)结肠癌患者。我们推测I期和IIA期结肠癌患者也会有类似获益。
通过根据TNM分期分析结果,对手术治疗临床结果试验的数据进行二次分析;早期(I期和IIA期,537例患者)和晚期(IIB期和III期,254例患者)疾病。晚期(35.7%)患者的5年复发率高于早期(9.5%)患者。通过卡方检验比较早期和晚期挽救率、复发模式及首次检测方法。
复发的早期和晚期疾病患者的挽救率相同(分别为35.9%对37%;P = 0.9)。复发后二次手术后早期和晚期患者的中位生存期分别为51.2个月和35.8个月。早期和晚期首次复发的单部位无显著差异,但早期患者多处复发较少见(早期对晚期分别为3.6%对28.6%;P < 0.001)。复发的首次检测方法无显著差异:早期和晚期疾病分别为癌胚抗原(29.1%对37.4%)、计算机断层扫描(23.6%对26.4%)、胸部X线(7.3%对12.1%)和结肠镜检查(12.7%对8.8%)。
早期结肠癌患者有相似的复发部位,复发后治疗与晚期患者有相似获益;对早期患者实施监测指南是合适的。